The Cyprus Association of Pharmaceutical Companies (KEFEA) expresses its disappointment at the delay in the integration of new innovative medicines into the healthcare system, as it says in a statement.
The KEFEA says that the procedure for the inclusion of new medicines "remains complex and difficult, and needs immediate modernisation" and adds that the necessary upgrades should have been adopted before the implementation of the second phase of the YESY, based on the memorandum signed in 2019 by the Ministry of Health, the Health Insurance Organisation (HIO) and the pharmaceutical industry.
"According to the current legislation, drug companies must apply for inclusion of a drug in the Health System," it says, adding that the OAI through the Advisory Committees, has the "responsibility of deciding whether or not to include a drug in the system
(CNA)
CNA
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
